Medron Medical Systems Inc. is Introducing MVision’s Groundbreaking Auto-Segmentation Solution to Canada

Helsinki – December 9, 2021 – MVision AI, the leading software service provider of guideline-based AI segmentation, GBAIS™, for radiotherapy treatment planning, declares a new distribution partnership with Medron Medical Systems, Canada’s choice health equipment provider (subject to approval from Health Canada).

The collaboration authorizes Medron Medical Systems to distribute products and services of MVision AI throughout Canada. Medron Medical Systems and MVision AI are devoted to helping oncology departments receive exceptional and consistent radiotherapy machine learning solutions across Canada. MVision AI’s specialists will be collaborating with Medron Medical System Inc.’s experts to undertake the distribution of the finest, most convenient, and consistent radiotherapy services. 

“Innovation and the introduction of new modalities in radiation oncology have changed the landscape in how radiation therapy is delivered. The introduction of artificial intelligence (AI) in treatment planning is the beginning of a new era that will ultimately lead to greater accuracy in radiation dose delivery, leading to improved patient outcomes,” said Ronald Wallace, President of Medron Medical Systems Inc. 

“Medron Medical Systems Inc. is proud to partner with MVision in developing the Canadian market of their Automatic Segmentation platform using their unique AI algorithms.”

As stated by MVision AI’s CEO and Co-Founder, Mahmudul Hasan, “MVision is continuing its rapid expansion. We are excited to start this partnership with Medron Medical Systems Inc. for Canadian hospitals. We are well ahead of our mission to serve radiotherapy patients with fast and high-quality treatment plans.” 

For additional inquiries on Medron Medical System:

Medron Medical System

Website: https://www.medron.ca/

Email: info@medron.ca

Tel: +1 613-769-3302 

MVision AI is active on LinkedInTwitterFacebook, and Instagram. Follow us on social media and subscribe to our newsletter to stay up-to-date on the latest MVision AI news.

Are you eager to learn more about GBAIS™? We welcome you to contact MVision AI:

c/o Terkko Health Hub, Haartmaninkatu 4, 00290 Helsinki, Finland.

Tel: +358 (0) 40 5489 229

Website: https://www.mvision.ai 

Email: info@ mvision.ai 

For media inquiries:

Tel: +358 40 500 7915

Email: pr@mvision.ai

Our Newsletter

Subscribe to get information, latest news and other interesting offers about MVision AI

Related Posts

24.10.2024

MVision AI Secures FDA 510(k) Clearance for Contour+ Advanced CT and MR Models

Helsinki, October 2024 – MVision AI, a leading innovator in AI-powered solutions for radiotherapy, is thrilled to announce that its auto-contouring solution Contour+ has received FDA 510(k) clearance for three new models: Bones CT, Brain MR, and Male Pelvis MR T2, and five updated models: Brain CT, Abdomen & Lung…

Press Releases

22.10.2024

Saving Time to Improve Workflow and Patient Comfort: A New AI-Based Solution for Gynaecological Brachytherapy

Navigating Discomfort Radiation therapy is a non-invasive and non-painful cancer treatment. However, some patients might experience mild discomfort during treatment sessions, determined by a variety of factors. Physical discomfort due to positioning and immobilisation represent one of the most common causes [1]. Despite the medical team’s efforts, keeping the same…

Articles

11.10.2024

Baylor College of Medicine and MVision AI Collaborate to Drive AI-Powered Innovations in Radiation Therapy

Helsinki, Finland, October 11, 2024 – Baylor College of Medicine and MVision AI have entered into a strategic research and development agreement to drive innovation in radiation therapy through AI technology. This collaboration aims to accelerate the clinical adoption of AI-powered solutions, enhancing the efficiency and effectiveness of cancer treatment.…

Press Releases